AMGN vs CRL: Which Stock Is the Better Buy?
Amgen Inc. and Charles River Laboratories Inte side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — AMGN vs CRL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Amgen Inc. (AMGN) | Charles River Laboratories Inte (CRL) | |
|---|---|---|
| Market cap | $207.9B | — |
| Revenue (latest FY) | $36.75B | $4.02B |
| Net income (latest FY) | $7.71B | $-144.34M |
| Revenue growth (5y CAGR) | 7.6% | 6.5% |
| Net margin | 21.0% | -3.6% |
| Return on equity | 89.1% | -4.6% |
| P/E ratio | 26.8 | — |
| Dividend yield | 2.6% | — |
| Profitable years (of last 10) | 10 | 9 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full AMGN vs CRL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AMGN's full financials → Open CRL's full financials →More comparisons
Frequently asked questions
Which is bigger, AMGN or CRL?
Market capitalization data is not available for both companies.
Which grows faster, AMGN or CRL?
Over the last five fiscal years, Amgen Inc. grew revenue faster — 7.6%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.